| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dendritic Cells | 15 | 2020 | 402 | 3.000 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2021 | 393 | 1.640 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 186 | 1.500 |
Why?
|
| Immunologic Memory | 3 | 2021 | 180 | 1.410 |
Why?
|
| Th1 Cells | 8 | 2020 | 152 | 1.290 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 51 | 1.250 |
Why?
|
| Amino Acyl-tRNA Synthetases | 3 | 2024 | 27 | 1.180 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2021 | 501 | 1.170 |
Why?
|
| Immunotherapy | 7 | 2019 | 653 | 1.120 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2020 | 79 | 1.000 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2020 | 96 | 0.980 |
Why?
|
| Fetal Blood | 9 | 2013 | 177 | 0.970 |
Why?
|
| Adaptive Immunity | 2 | 2015 | 88 | 0.930 |
Why?
|
| T-Lymphocytes | 8 | 2020 | 1676 | 0.820 |
Why?
|
| Immunity, Innate | 2 | 2015 | 372 | 0.810 |
Why?
|
| Cytokines | 4 | 2025 | 1281 | 0.800 |
Why?
|
| Dog Diseases | 2 | 2020 | 49 | 0.790 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 531 | 0.770 |
Why?
|
| Homeostasis | 2 | 2024 | 682 | 0.760 |
Why?
|
| Receptors, IgG | 1 | 2021 | 54 | 0.720 |
Why?
|
| CD40 Antigens | 2 | 2012 | 24 | 0.720 |
Why?
|
| Immune System | 1 | 2020 | 87 | 0.700 |
Why?
|
| Neoplasms | 9 | 2020 | 2762 | 0.680 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2024 | 0.670 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 203 | 0.670 |
Why?
|
| Vaccination | 5 | 2019 | 949 | 0.660 |
Why?
|
| Animals | 36 | 2025 | 33708 | 0.630 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 38 | 0.620 |
Why?
|
| Doxorubicin | 1 | 2019 | 301 | 0.570 |
Why?
|
| Peptides | 3 | 2020 | 794 | 0.570 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 45 | 0.560 |
Why?
|
| Antigens, Neoplasm | 4 | 2025 | 388 | 0.550 |
Why?
|
| Neoplasm Proteins | 2 | 2025 | 669 | 0.550 |
Why?
|
| Bystander Effect | 1 | 2016 | 7 | 0.540 |
Why?
|
| B7 Antigens | 1 | 2016 | 11 | 0.530 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 118 | 0.530 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 157 | 0.520 |
Why?
|
| Porins | 6 | 2001 | 41 | 0.510 |
Why?
|
| Cytosol | 1 | 2015 | 159 | 0.490 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 52 | 0.490 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 992 | 0.450 |
Why?
|
| Immunomodulation | 2 | 2024 | 81 | 0.450 |
Why?
|
| Mice | 25 | 2025 | 17483 | 0.440 |
Why?
|
| Mice, Inbred BALB C | 6 | 2020 | 1001 | 0.430 |
Why?
|
| Interferon-gamma | 8 | 2017 | 510 | 0.430 |
Why?
|
| Stress, Physiological | 1 | 2015 | 260 | 0.410 |
Why?
|
| Vaccines | 1 | 2017 | 369 | 0.400 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2011 | 20 | 0.380 |
Why?
|
| AIDS Vaccines | 1 | 2011 | 30 | 0.380 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 572 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 183 | 0.370 |
Why?
|
| Th2 Cells | 2 | 2007 | 187 | 0.340 |
Why?
|
| Influenza Vaccines | 3 | 2012 | 473 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2025 | 333 | 0.330 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 375 | 0.330 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 319 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 5 | 2024 | 4342 | 0.310 |
Why?
|
| Humans | 41 | 2025 | 123122 | 0.310 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 300 | 0.300 |
Why?
|
| Exotoxins | 1 | 2007 | 44 | 0.300 |
Why?
|
| Anthrax Vaccines | 1 | 2007 | 26 | 0.290 |
Why?
|
| Anthrax | 1 | 2007 | 30 | 0.290 |
Why?
|
| Influenza, Human | 2 | 2012 | 649 | 0.290 |
Why?
|
| Bacillus anthracis | 1 | 2007 | 39 | 0.290 |
Why?
|
| Communicable Diseases | 1 | 2009 | 162 | 0.280 |
Why?
|
| Cell Polarity | 1 | 2007 | 124 | 0.280 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 176 | 0.270 |
Why?
|
| Plasmids | 1 | 2007 | 510 | 0.270 |
Why?
|
| Cells, Cultured | 8 | 2019 | 3046 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 666 | 0.250 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 314 | 0.250 |
Why?
|
| Antigens, CD34 | 6 | 2012 | 106 | 0.240 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 53 | 0.240 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2813 | 0.240 |
Why?
|
| Plasma Cells | 1 | 2025 | 54 | 0.240 |
Why?
|
| Ion Channels | 4 | 1999 | 188 | 0.240 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2010 | 532 | 0.230 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1907 | 0.230 |
Why?
|
| Antigens, CD | 6 | 2009 | 420 | 0.230 |
Why?
|
| Antibodies | 1 | 2005 | 370 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2025 | 400 | 0.220 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 3 | 2013 | 13 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1580 | 0.220 |
Why?
|
| Lymphocyte Activation | 5 | 2009 | 676 | 0.210 |
Why?
|
| Cell Proliferation | 5 | 2015 | 2306 | 0.210 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3267 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 325 | 0.210 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 32 | 0.200 |
Why?
|
| Carcinogenesis | 2 | 2015 | 327 | 0.200 |
Why?
|
| Vaccines, Synthetic | 2 | 2017 | 312 | 0.200 |
Why?
|
| Sezary Syndrome | 2 | 2014 | 12 | 0.200 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4267 | 0.190 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 102 | 0.190 |
Why?
|
| Alternative Splicing | 3 | 2000 | 345 | 0.190 |
Why?
|
| Dogs | 2 | 2020 | 765 | 0.190 |
Why?
|
| Immunophenotyping | 3 | 2019 | 330 | 0.180 |
Why?
|
| Adenoviridae | 2 | 2017 | 605 | 0.180 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2013 | 59 | 0.180 |
Why?
|
| Multiple Myeloma | 2 | 2013 | 169 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2020 | 21 | 0.180 |
Why?
|
| Exons | 2 | 2000 | 795 | 0.180 |
Why?
|
| Mitochondria, Muscle | 1 | 2000 | 34 | 0.170 |
Why?
|
| Arthralgia | 1 | 2020 | 56 | 0.170 |
Why?
|
| History, 19th Century | 2 | 2011 | 117 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 193 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 560 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2024 | 509 | 0.160 |
Why?
|
| Bone Marrow Purging | 2 | 2011 | 34 | 0.160 |
Why?
|
| Osteoarthritis | 1 | 2020 | 87 | 0.160 |
Why?
|
| Amino Acid Sequence | 4 | 2020 | 2697 | 0.160 |
Why?
|
| History, 20th Century | 2 | 2011 | 383 | 0.160 |
Why?
|
| Intracellular Space | 2 | 2016 | 48 | 0.160 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 92 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 250 | 0.150 |
Why?
|
| Macrophages | 2 | 2015 | 603 | 0.150 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 288 | 0.150 |
Why?
|
| Membrane Glycoproteins | 3 | 2012 | 414 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2847 | 0.150 |
Why?
|
| Interleukin-12 | 2 | 2009 | 113 | 0.150 |
Why?
|
| CD3 Complex | 4 | 2013 | 82 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 473 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2015 | 477 | 0.140 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 65 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2020 | 4493 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 98 | 0.140 |
Why?
|
| CD40 Ligand | 2 | 2007 | 64 | 0.140 |
Why?
|
| Antigen Presentation | 3 | 2015 | 105 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 533 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 216 | 0.130 |
Why?
|
| Voltage-Dependent Anion Channels | 6 | 2001 | 30 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 240 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 211 | 0.130 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 12 | 0.130 |
Why?
|
| Cell Separation | 4 | 2011 | 232 | 0.130 |
Why?
|
| Immunological Synapses | 2 | 2012 | 26 | 0.130 |
Why?
|
| Monocytes | 2 | 2016 | 346 | 0.130 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 16 | 0.130 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 54 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2015 | 17 | 0.120 |
Why?
|
| Female | 9 | 2024 | 65443 | 0.120 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 123 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1240 | 0.120 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2015 | 3 | 0.120 |
Why?
|
| Dinoprostone | 2 | 2022 | 76 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 467 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2015 | 34 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 350 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 2528 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 14 | 0.120 |
Why?
|
| Flow Cytometry | 4 | 2012 | 803 | 0.120 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 793 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 664 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1470 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2017 | 934 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 352 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2013 | 262 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 217 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2012 | 752 | 0.100 |
Why?
|
| Influenza in Birds | 1 | 2012 | 27 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 313 | 0.100 |
Why?
|
| Mitochondria | 5 | 2001 | 677 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 51 | 0.100 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2012 | 10 | 0.100 |
Why?
|
| Fucose | 1 | 2012 | 21 | 0.100 |
Why?
|
| Vaccines, Inactivated | 1 | 2012 | 144 | 0.100 |
Why?
|
| Influenza A virus | 1 | 2013 | 135 | 0.100 |
Why?
|
| Protein Isoforms | 4 | 2001 | 408 | 0.100 |
Why?
|
| Cell Movement | 1 | 2015 | 831 | 0.100 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2009 | 47 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2012 | 243 | 0.100 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 3868 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2012 | 122 | 0.090 |
Why?
|
| History, 18th Century | 1 | 2011 | 69 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 62 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 48 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 38 | 0.090 |
Why?
|
| Pyrazines | 1 | 2011 | 73 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 80 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 497 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 195 | 0.090 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 50 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2011 | 272 | 0.090 |
Why?
|
| Mice, SCID | 4 | 2013 | 571 | 0.090 |
Why?
|
| Transplantation, Autologous | 2 | 2011 | 296 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 287 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1265 | 0.080 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 258 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2008 | 392 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2010 | 436 | 0.080 |
Why?
|
| Glycerol Kinase | 2 | 1999 | 19 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2009 | 168 | 0.080 |
Why?
|
| Langerhans Cells | 1 | 2008 | 21 | 0.080 |
Why?
|
| Inflammation | 1 | 2015 | 1402 | 0.080 |
Why?
|
| Transfection | 2 | 2008 | 1067 | 0.070 |
Why?
|
| K562 Cells | 3 | 2014 | 95 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 430 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 159 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 164 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1672 | 0.070 |
Why?
|
| Mice, Inbred NOD | 3 | 2013 | 285 | 0.070 |
Why?
|
| X Chromosome | 2 | 1999 | 337 | 0.070 |
Why?
|
| Species Specificity | 1 | 2007 | 549 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2008 | 170 | 0.070 |
Why?
|
| Myocardium | 1 | 2011 | 984 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 659 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 38 | 0.060 |
Why?
|
| Evolution, Molecular | 2 | 1999 | 672 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2006 | 77 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 84 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 85 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 98 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1012 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 45 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 105 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 368 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2010 | 518 | 0.060 |
Why?
|
| Male | 8 | 2021 | 60036 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12121 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2010 | 801 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 239 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 243 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1001 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2044 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2025 | 269 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 665 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 876 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 879 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1677 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1012 | 0.050 |
Why?
|
| Interleukin-2 | 2 | 2013 | 229 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1089 | 0.050 |
Why?
|
| Base Sequence | 3 | 2000 | 3091 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2001 | 93 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2017 | 527 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6373 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 69 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2005 | 810 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2013 | 287 | 0.040 |
Why?
|
| Cannabis | 1 | 2020 | 41 | 0.040 |
Why?
|
| Cell Survival | 3 | 2011 | 803 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 287 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2013 | 3714 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2000 | 203 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2000 | 60 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 284 | 0.040 |
Why?
|
| Biomarkers | 1 | 2009 | 2941 | 0.040 |
Why?
|
| Lod Score | 1 | 1999 | 120 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2013 | 233 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1999 | 65 | 0.040 |
Why?
|
| Retroelements | 1 | 1999 | 41 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 78 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2000 | 293 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1999 | 1081 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1999 | 118 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2012 | 340 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 623 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2001 | 262 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1999 | 454 | 0.040 |
Why?
|
| Genetic Markers | 1 | 1999 | 609 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1385 | 0.040 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 937 | 0.040 |
Why?
|
| Pericytes | 1 | 2017 | 23 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 94 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2017 | 78 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 105 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1589 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 3 | 2001 | 23 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 237 | 0.030 |
Why?
|
| Phytochemicals | 1 | 2015 | 8 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 102 | 0.030 |
Why?
|
| Receptors, CCR4 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2015 | 61 | 0.030 |
Why?
|
| Adult | 2 | 2012 | 29030 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1592 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2015 | 144 | 0.030 |
Why?
|
| United States | 1 | 2009 | 10626 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 1 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2013 | 3 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 1758 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 25 | 0.030 |
Why?
|
| Aged | 3 | 2021 | 19072 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2001 | 1101 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 12 | 0.030 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2012 | 11 | 0.030 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 1 | 2012 | 11 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 57 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2012 | 113 | 0.030 |
Why?
|
| Birds | 1 | 2012 | 85 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 348 | 0.030 |
Why?
|
| Axin Protein | 1 | 2012 | 18 | 0.020 |
Why?
|
| Casein Kinase I | 1 | 2012 | 12 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 368 | 0.020 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2012 | 61 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1682 | 0.020 |
Why?
|
| Dishevelled Proteins | 1 | 2012 | 43 | 0.020 |
Why?
|
| Arabinofuranosyluracil | 1 | 2011 | 4 | 0.020 |
Why?
|
| Middle Aged | 3 | 2021 | 25971 | 0.020 |
Why?
|
| Lymphography | 1 | 2011 | 12 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 60 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2011 | 88 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 26 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 37 | 0.020 |
Why?
|
| Cell Line | 2 | 2011 | 2772 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 253 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 714 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 41 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 73 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 272 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1998 | 1527 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 2010 | 8 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 2010 | 7 | 0.020 |
Why?
|
| Perforin | 1 | 2010 | 17 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2010 | 26 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2012 | 137 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 369 | 0.020 |
Why?
|
| beta Catenin | 1 | 2012 | 205 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 568 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 294 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 155 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 384 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 399 | 0.020 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 2 | 1999 | 17 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2009 | 14 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2009 | 7 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 57 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 375 | 0.020 |
Why?
|
| Prostate | 1 | 2012 | 421 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2009 | 64 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2009 | 35 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 182 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 531 | 0.020 |
Why?
|
| Receptor, EphA4 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Brain | 1 | 2000 | 2945 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 37 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 340 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2008 | 36 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 44 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1154 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1610 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 216 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4507 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1741 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5771 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 966 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 900 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 372 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 812 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 1999 | 462 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 333 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 1134 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 45 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2006 | 35 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 350 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1062 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2006 | 55 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 44 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2006 | 40 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2006 | 78 | 0.020 |
Why?
|
| Benzamides | 1 | 2006 | 107 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 141 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2006 | 169 | 0.020 |
Why?
|
| Gene Expression | 2 | 1999 | 1565 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1231 | 0.010 |
Why?
|
| Piperazines | 1 | 2006 | 231 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1062 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1441 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 670 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 420 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 369 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 374 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 1090 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 376 | 0.010 |
Why?
|
| Electron Transport | 1 | 2001 | 54 | 0.010 |
Why?
|
| Sperm Count | 1 | 2001 | 75 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 258 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 6204 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 391 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 382 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3527 | 0.010 |
Why?
|
| Electron Transport Complex IV | 1 | 1999 | 39 | 0.010 |
Why?
|
| Yeasts | 1 | 1999 | 42 | 0.010 |
Why?
|
| Eukaryotic Cells | 1 | 1999 | 31 | 0.010 |
Why?
|
| Lipid Bilayers | 1 | 1999 | 46 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1999 | 64 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 4221 | 0.010 |
Why?
|
| NAD | 1 | 1999 | 48 | 0.010 |
Why?
|
| Permeability | 1 | 1999 | 118 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1999 | 179 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1998 | 129 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 123 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 268 | 0.010 |
Why?
|
| Liposomes | 1 | 1999 | 168 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1999 | 303 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 444 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 766 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 147 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 462 | 0.010 |
Why?
|
| Introns | 1 | 1998 | 302 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 1196 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 405 | 0.010 |
Why?
|
| COS Cells | 1 | 1996 | 273 | 0.010 |
Why?
|
| RNA | 1 | 1999 | 572 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8101 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 657 | 0.010 |
Why?
|